Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
G蛋白偶联受体/G蛋白
内分泌学/激素
/ SSTR / Lanreotide/兰瑞肽

Lanreotide/兰瑞肽 {[allProObj[0].p_purity_real_show]}

货号：A218062 同义名： BIM 23014; Laromustine

Lanreotide是一种合成的环状八肽，类 somatostatin，能够抑制 somatostatin 受体 2（SSTR-2）。

Lanreotide/兰瑞肽 化学结构 CAS号：108736-35-2
Lanreotide/兰瑞肽 化学结构
CAS号：108736-35-2
Lanreotide/兰瑞肽 3D分子结构
CAS号：108736-35-2
Lanreotide/兰瑞肽 化学结构 CAS号：108736-35-2
Lanreotide/兰瑞肽 3D分子结构 CAS号：108736-35-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Lanreotide/兰瑞肽 纯度/质量文件 产品仅供科研

货号：A218062 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Nat. Electron., 2025, 8, 66-74. Ambeed. [ A100095 ]
• Adv. Mater., 2025, 2416621. Ambeed. [ A255324 , A420052 ]
• Adv. Mater., 2025, 2410493. Ambeed. [ A838608 ]
• Adv. Mater., 2025, 2420319. Ambeed. [ A106129 ]
更多 >

Lanreotide/兰瑞肽 生物活性

描述 Lanreotide (LAN), a synthetic cyclic octapeptide, is the analogue of somatostatin that can inhibit somatostatin receptor 2 (SSTR-2). Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides[3]. Lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs (neuroendocrine tumors) originated by intestinal sites[4]. Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2[5]. Lanreotide treatment for 3 months before trans-sphenoidal surgery effectively reduced tumour size, and improved surgical cure rate, in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma[6].

Lanreotide/兰瑞肽 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02668172 Acromegaly Phase 4 Unknown June 2017 Netherlands ... 展开 >> Erasmus Medical Center Rotterdam, South Holland, Netherlands, 3000CA 收起 <<
NCT01677910 Carcinoid Syndrome Phase 3 Completed - -
NCT00642720 Quality of Life ... 展开 >> Acromegaly 收起 << Phase 4 Completed - -

Lanreotide/兰瑞肽 参考文献

[1]Michael M, Garcia-Carbonero R, et al. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist. 2017 Mar;22(3):272-285.

[2]Tong H, Wei B, et al. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017 Feb 24.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Lanreotide. 2017 Apr 11

[4]Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol. 2020 Jul 7;10:1047

[5]Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33

[6]Li ZQ, Quan Z, Tian HL, Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res. 2012;40(2):517-24

Lanreotide/兰瑞肽 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.91mL

0.18mL

0.09mL

4.56mL

0.91mL

0.46mL

9.12mL

1.82mL

0.91mL

Lanreotide/兰瑞肽 技术信息

CAS号108736-35-2
分子式C54H69N11O10S2
分子量 1096.32
SMILES Code O=C([C@@H](NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSC[C@H](NC([C@H](N)CC5=CC=C6C=CC=CC6=C5)=O)C4=O)N[C@@H]([C@H](O)C)C(N)=O
MDL No. MFCD03424071
别名 BIM 23014; Laromustine; Lanreotidum; ITM-014T; ITM-014; Dermopeptin; BM 23014; BIM 23014C; Angiopeptin
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, sealed in dry, store in freezer, under -20°C

Tags: Lanreotide | 108736-35-2 | BIM 23014 | BIM23014 | BIM-23014 | Peptides | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Lanreotide/兰瑞肽 纯度/质量文件 | Lanreotide/兰瑞肽 生物活性 | Lanreotide/兰瑞肽 临床数据 | Lanreotide/兰瑞肽 参考文献 | Lanreotide/兰瑞肽 实验方案 | Lanreotide/兰瑞肽 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z